NeuroDex research library
Methods: extracellular vesicles, blood vs CSF and target engagement
Most plasma biomarkers reflect signal from anywhere in the body. Extracellular vesicles released by brain cells carry proteins and RNA from the cells that made them, which gives a blood sample a CNS address. These articles explain the biology, compare blood with CSF and PET, and show how target engagement can be measured without a lumbar puncture.
Extracellular vesicles
What Are Neuron-Derived Extracellular Vesicles (NDEs) and How Are They Isolated From Blood?Neuron-derived extracellular vesicles (NDEs) carry neuronal proteins and RNA into blood. Learn how NDEs are isolated from plasma and what they…How Extracellular Vesicles Carry Biomarkers from the Brain to BloodHow neurons, astrocytes, microglia and oligodendrocytes release EVs, how they cross the blood-brain barrier, and which biomarkers they carry into…ExosomesExosomes are small extracellular vesicles (30–150 nm) that cells release into body fluids. Learn what they are, what they carry and why they matter.Extracellular Vesicles in Neuroscience: A Definitive Guide for ResearchersExplore how Extracellular Vesicles serve as vital biomarkers for neurological disorders in this definitive research guide.Exosomes: The Unseen Players in Neurodegenerative DiseasesExosomes, once thought to be mere cellular debris, have emerged as significant players in neurodegenerative diseases.Why NDE-Based Biomarkers Are Having a MomentDiscover why NDE-based biomarkers are enabling earlier, more CNS-specific blood tests for Alzheimer’s, Parkinson’s, ALS, and other neurodegenerative…Isolating Neuron-Derived Vesicles from Blood: What the L1CAM Debate Means for Biomarker DataExplore methods for isolating neuron-derived vesicles and insights into the L1CAM debate in this comprehensive analysis.NeuroDex Publishes Validated Workflow for Isolating Tissue-Specific Extracellular Vesicles From BloodDiscover NeuroDex’s new method for isolating tissue-specific extracellular vesicles from blood for neurological disorder research.NeuroDex Contributes to Landmark Review on Tissue-Specific Extracellular Vesicles and the Future of Liquid BiopsyDiscover how NeuroDex plays a vital role in the review of tissue-specific extracellular vesicles and the potential of liquid biopsy with NeuroDex.
Blood, CSF and PET
Blood vs. CSF vs. PET Biomarkers: Which to Use for Brain Diseases and CNS TrialsExplore blood, CSF, and PET biomarkers compared for Alzheimer’s, Parkinson’s, and CNS trials, focusing on blood vs CSF vs PET biomarkers.CSF Sampling Doesn’t Scale: The Case for Blood-Based CNS BiomarkersDiscover the benefits of blood-based CNS biomarkers over CSF sampling for diagnosing neurological disorders.Why CSF Biomarkers Break Down in Late-Stage CNS TrialsDiscover why CSF biomarkers often break down in Phase II and III CNS trials and what blood-based biomarkers may offer as an alternative.NfL Has Earned Its Place in CNS Trials, But It’s Not Enough. Here’s What It Can’t Tell You.Plasma NfL is the most validated blood biomarker in neurodegeneration. Here’s an honest account of what it measures well — and where it stops being…NfL vs. Neuron-Derived Vesicle Biomarkers: Measuring Damage vs. Mechanism in CNS TrialsDiscover insights on NfL vs neuron-derived exosome biomarkers for CNS target engagement and neuronal health.Brain-Specific Biomarkers in Blood: Why Provenance Matters More Than SensitivityMost plasma biomarkers reflect damage anywhere in the body. Why CNS provenance is the real problem for blood tests of the brain, and how to solve it.Liquid Biopsy for Neurological Diseases: How It WorksExplore how Liquid Biopsy transforms diagnosing neurological diseases at NeuroDex. Discover its significant impact today!Liquid Biopsy for Neurodegenerative DiseasesDiscover how liquid biopsy is transforming the diagnosis of neurodegenerative diseases in our latest NeuroDex blog post.
Target engagement
Measuring CNS Target Engagement Without a Spinal TapNeuron-derived EVs offer a blood-based route to repeated pharmacodynamic readouts. How Do You Measure CNS Target Engagement Without a Lumbar Puncture?Did Your GLP-1 Drug Reach the Brain? Measuring CNS Target Engagement from a Blood SampleDiscover if your GLP-1 drug reached the brain by measuring GLP-1 CNS target engagement from neuron-derived extracellular vesicle biomarkers in blood.NeuroDex and Stanford Researchers Publish First Evidence of CNS Target Engagement for GLP-1 and PPARγ Agonists Using Blood-Based Neuron-Derived Extracellular VesiclesDiscover NeuroDex and Stanford’s findings on GLP-1 and PPARγ agonists through neuron-derived extracellular vesicles.IRS1 in Blood: Unlocking Neurodegenerative Disease Detection with Liquid BiopsyDiscover how IRS1 in blood transforms neurodegenerative disease detection and improves patient care through liquid biopsy technology.NF-κB: Unraveling the Master Regulator of Immune and Inflammatory ResponsesDiscover how NF-κB influences immune responses and its significance in health and disease.
Biomarker basics
BiomarkersA biomarker is a measurable indicator of a biological process, disease or response to treatment. Learn the main types of biomarkers and how they are…Types of Biomarkers Explained: Diagnostic, Prognostic, Predictive, Pharmacodynamic and MoreExplore the various types of biomarkers, including diagnostic, prognostic, and safety, with CNS examples and insights on their use. Types of…Glossary of CNS Biomarker Terms: From NDEs and SAA to CLIA, GCLP and LATEExplore our plain-language CNS biomarker glossary, clarifying vital terms for better understanding and insights into neurobiology.Understanding Biomarker Analysis in MedicineDiscover the transformative power of biomarker analysis in medicine. Learn about its role in disease diagnosis, personalized treatments.Biomarker discovery servicesDiscover how our Biomarker Discovery Services at NeuroDex utilize advanced technologies to identify and validate novel biomarkersBiomarkers as Game-Changers in Neurodegenerative Disease DiagnosticsDiscover how biomarkers as game-changers in neurodegenerative diseases can lead to early prediction and treatment.Next-Generation Biomarkers for NeurodegenerationExplore advancements in biomarkers for neurodegeneration and their role in early diagnosis and treatment options.Neurodegenerative Diseases OverviewDiscover the neurodegenerative diseases like Alzheimer’s and Parkinson’s on millions worldwide in this Neurodegenerative Diseases Overview.
Assays
ELLA™ Glial Fibrillary Acidic Protein (GFAP)ImmunoassayValidated ELLA™ plasma GFAP immunoassay for neurodegenerative disease trials: linearity, precision, recovery and stability, run in CLIA/GCLP labs.ELLA™ Neurofilament Light Chain (NF-L) ImmunoassayValidated ELLA™ plasma neurofilament light (NfL) immunoassay for ALS, Alzheimer’s and Parkinson’s trials, run in CLIA-certified, GCLP labs.
Other conditions
Huntington’s DiseaseExplore insights on Huntington’s Disease, treatment options, and support for affected families.Huntington’s Disease Latest Research, Biomarker Discoveries, and Promising TreatmentsExplore recent research on Huntington’s Disease, biomarker discoveries, and promising treatments shaping the future of HD care.Blood Biomarkers for Rare Neurological DiseasesDiscover how Blood Biomarkers aid in diagnosing rare neurological diseases and their significance for future treatments.

